Welcome to our dedicated page for Nervgen Pharma news (Ticker: NGENF), a resource for investors and traders seeking the latest updates and insights on Nervgen Pharma stock.
NervGen Pharma Corp. (NGENF) generates news primarily as a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. Newsflow around NervGen often centers on clinical data from its Phase 1b/2a CONNECT SCI Study of its lead candidate NVG-291, regulatory interactions, financing activities, and capital markets developments.
Investors following NGENF news can expect detailed updates on NVG-291’s clinical progress, including topline and expanded data from the chronic cohort of the CONNECT SCI Study and ongoing enrollment in the subacute cohort. Company announcements have highlighted durable improvements in function, independence, and quality of life in individuals with chronic SCI, supported by neurophysiological measures such as changes in corticospinal and reticulospinal signaling. These releases provide insight into how NervGen interprets the efficacy profile and potential impact of NVG-291.
NervGen’s news also covers regulatory milestones, such as FDA Type C meetings and planned End-of-Phase 2 discussions, as well as designations like Fast Track from the FDA and Orphan Drug status from the EMA for spinal cord injury. Capital markets and corporate updates, including non-brokered private placements, at-the-market equity program activity, and the company’s approval for listing on Nasdaq under the symbol NGEN, are additional recurring themes.
Preclinical research updates, particularly Department of Defense–sponsored studies of NVG-291-R in models of traumatic hearing loss and peripheral nerve injury, further contribute to the news stream by illustrating the broader therapeutic potential of NervGen’s technology. For readers tracking NGENF, this news page offers a centralized view of clinical, regulatory, financing, and strategic developments as the company advances its neuroreparative pipeline.
NervGen Pharma (OTCQB: NGENF) has provided an update on its at-the-market (ATM) equity program for Q1 2025. During the quarter ending March 31, 2025, the company, through its agent Stifel Nicolaus Canada, issued and sold 564,500 common shares at a weighted average price of $2.91 per share.
The ATM Program, which was launched on December 19, 2024, generated aggregate gross proceeds of $1,639,761. After paying cash placement fees of $32,796 to the agent, the company secured net proceeds of $1,606,965.
NervGen Pharma (NGENF) has reported its 2024 year-end financial results and key developments. The company completed enrollment in the chronic cohort of its Phase 1b/2a clinical trial for NVG-291 in spinal cord injury (SCI), with topline data expected in early June 2025. The company also initiated enrollment in the subacute cohort and received FDA approval for an expanded access protocol.
Financial highlights include a cash position of $17.3 million as of December 31, 2024, bolstered by a $23 million bought deal financing. R&D expenses increased to $15.7 million from $8.0 million in 2023, while G&A expenses decreased to $9.2 million from $9.7 million. The company reported a net loss of $24.0 million ($0.36 per share) for 2024.
The company's pipeline candidate NVG-300 showed promising preclinical results in ischemic stroke and SCI models, demonstrating decreased lesion volume and improved functional outcomes.
NervGen Pharma (TSXV: NGEN) (OTCQB: NGENF) has initiated an expanded access policy for its investigational drug NVG-291 following FDA clearance. The policy will allow specific individuals with spinal cord injury (SCI) who have participated in NervGen's clinical trials to continue accessing the treatment.
The company received and processed a physician's request for expanded access for a subject from the chronic cohort of their Phase 1b/2a clinical trial. NVG-291, still in clinical development and not yet approved for market use, has unknown efficacy and potential risks for SCI treatment.
NervGen continues to enroll participants in the subacute cohort of the Phase 1b/2a study, with plans to unblind the efficacy and safety results from the chronic cohort in early June 2025.
NervGen Pharma (OTCQB: NGENF) has announced a virtual investor event scheduled for April 9, 2025, at 10:00 a.m. ET, focusing on their spinal cord injury treatment developments. The event will feature key opinion leaders Dr. Monica Perez from Shirley Ryan AbilityLab and Dr. Steven Kirshblum from Rutgers New Jersey Medical School.
The presentation will cover:
- Current treatment landscape for spinal cord injury patients
- Overview of NervGen's Phase 1b/2a proof-of-concept clinical trial
- Discussion of study endpoints, including electrophysiology
- Review of preclinical data for NVG-291-R
- Phase 1 safety trial results for NVG-291, their first-in-class therapeutic peptide
Clinical data from the Phase 1b/2a trial is expected in the second quarter. The event will conclude with a live Q&A session.
NervGen Pharma (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company focused on neurorestorative therapeutics, has announced the granting of 545,000 incentive stock options to employees and consultants. The options include:
- 100,000 options to company officers
- 15,000 options to investor relations consultants
- Exercise price set at $2.74 per share
The options are structured in two categories: 15,000 options with a five-year term vesting quarterly over one year, and 530,000 options with a ten-year term vesting semi-annually over two years. All grants comply with TSX Venture Exchange policies and the company's stock option plan.
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company focused on neurorestorative therapeutics, has announced its upcoming presentation at the Virtual Life Sciences Investor Forum.
The company's President & CEO, Mike Kelly, will present on Thursday, March 13, 2025, at 12:00 p.m. EDT. The management team will be available for one-on-one virtual investor meetings during March 13-14 and March 17-18, 2025.
Individual and institutional investors, advisors, and analysts can pre-register for this interactive online event at VirtualInvestorConferences.com. For those unable to attend live, an archived webcast will be available on NervGen's website after the event.
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company focused on neurorestorative therapeutics, has announced the granting of 627,200 incentive stock options. The options were distributed to company employees, with 505,200 options allocated to Officers. These options are exercisable at $2.97 per share with a 10-year duration and vest equally every six months over a two-year period. The grants comply with TSX Venture Exchange policies and the company's stock option plan.
NervGen Pharma has announced the dosing of its first subject in the subacute cohort of its Phase 1b/2a clinical trial for NVG-291, targeting spinal cord injury (SCI) treatment. The trial (NCT05965700) is designed as a proof-of-concept, double-blind, randomized placebo-controlled study.
The company has implemented protocol amendments for the subacute cohort, including revising the timing window to 20-90 days post-injury and reducing the number of visits and assessments to decrease participant burden. The trial evaluates efficacy in two separate cohorts: chronic and subacute cervical spinal cord injury.
Results for the chronic cohort, which has completed enrollment, are expected in Q2 2025. The company plans to continue enrollment in the subacute cohort throughout 2025.
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company focused on neurorestorative therapeutics, has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's President & CEO, Mike Kelly, will engage in a fireside chat on February 11, 2025, at 8:40 a.m. EST.
The conference, scheduled for February 11-12, 2025, will be held in a virtual format. NervGen's management team will be available for one-on-one virtual meetings with investors throughout the conference. A webcast of the presentation will be made available and archived for later viewing.
NervGen Pharma has completed enrollment of 20 subjects in the chronic cohort of its Phase 1b/2a clinical trial for NVG-291, its lead candidate for spinal cord injury (SCI) treatment. The company expects to release topline data in Q2 2025 after completing data collection, review, database lock, unblinding, and analysis.
The company has also received IRB approval for a protocol amendment and begun screening subjects for the subacute cohort. The trial (NCT05965700) is designed as a proof-of-concept, double-blind, randomized placebo-controlled study.
Management believes their experience from recruiting the chronic cohort, combined with the recently approved protocol amendment, will improve the recruitment process for the subacute cohort while reducing the burden on participants.
FAQ
What is the current stock price of Nervgen Pharma (NGENF)?
What is the market cap of Nervgen Pharma (NGENF)?
